How to combine capmatinib with other targeted drugs

Capmatinib (Capmatinib) is a highly selective MET inhibitor, mainly used to treat MET exons Patients with non-small cell lung cancer (NSCLC) with skip mutations in pan>14 (METex14). It blocks the growth, division and metastasis of tumor cells by inhibiting the MET signaling pathway. It is currently one of the key targeted drugs used clinically for MET abnormalities. Since MET mutations often co-exist with other driver gene abnormalities, capmatinib is often considered to be used in combination with other targeted drugs in actual treatment to improve efficacy and delay drug resistance.

In terms of combination therapy, capmatinib can be used in combination with EGFR inhibitors to deal with secondary resistance caused by EGFR mutationsNSCLC patients with MET amplification. For example, for patients who initially take EGFR-TKIs such as erlotinib and osimertinib, when the disease progresses and MET-mediated resistance mechanisms develop, capmatinib can be used in combination to achieve "vertical pathway" inhibition, thereby restoring or prolonging sensitivity to EGFR-targeted therapy. This combination strategy has initially shown good efficacy in multiple clinical studies.

In addition, capmatinib is also being studied in combination with ALK or ROS1 inhibitors to deal with complex tumors with multiple driver gene abnormalities. This type of combination strategy is especially suitable for patients with high tumor heterogeneity or poor response to a single targeted drug. Through coordinated inhibition of multiple pathways and multiple targets, it is expected to achieve deeper tumor control. However, this combination treatment may also bring risks such as toxicity superposition and drug interaction, so it needs to be carried out under strict monitoring to avoid serious side effects.

In general, capmatinib has shown significant efficacy in the monotherapy of MET mutated lung cancer, and has greater potential in combination therapy. Currently, many clinical trials are actively exploring its combination with other targeted drugs, immunotherapy or chemotherapy drugs. In the future, it is expected to provide personalized treatment options for more patients with complex mutations. Before combined use, it is recommended to fully understand the mutation background through genetic testing and formulate a treatment plan under the guidance of a professional doctor to maximize the efficacy and reduce side effects.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib